Humana Inc (HUM)
適正価値ファンダメンタル
57
株価
$376.91
時価総額
$46.79B
パート1 · 企業の価値
概要
Humana Inc. provides medical and specialty insurance products in the United States. It operates in two segments, Insurance and CenterWell. The Insurance segment offers individual Medicare Advantage products, including health insurance benefits, including wellness programs, chronic care management, and care coordination; individual Medicare stand-alone prescription drug products (PDP); group Medicare advantage and Medicare stand-alone PDP; Medicare supplements; specialty and ancillary insurance comprising dental, vision, life and disability; and administrative services to arrange health care services for active-duty and retired military personnel and dependents, as well as pharmacy benefit managers. Its CenterWell segment operates full-service, value-based senior focused primary care centers under the Conviva Senior Primary Care and CenterWell Senior Primary Care brands; a management services organization; CenterWell Home Health, a home health provider; and OneHome, which manages post-acute patient needs, as well as provides pharmacy and hospice solutions. The company was formerly known as Extendicare Inc. and changed its name to Humana Inc. in April 1974. Humana Inc. was founded in 1961 and is headquartered in Louisville, Kentucky.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
Generated on 2026年9月18日 with claude-haiku-4-5 — shared with all users
Its UnitedHealthcare arm is the largest Medicare Advantage insurer in the United States and bids against Humana plan-by-plan for the same senior enrollees, while its Optum clinics and pharmacy mirror Humana's CenterWell care-delivery model.
Through Aetna it is the third-largest Medicare Advantage insurer and also sells Medicare drug plans, Medicaid managed care and commercial coverage to the same customers Humana serves.
A national managed-care company competing with Humana for Medicare Advantage seniors and for state Medicaid contracts in overlapping markets.
Competes head-on for government-sponsored members, bidding for the same state Medicaid contracts and selling Medicare Advantage and Part D plans to low-income and dual-eligible beneficiaries.
A non-profit integrated insurer-and-provider holding about 6% of Medicare Advantage enrollment, taking the same seniors in California and other western markets with the combined coverage-plus-clinics model Humana is building.
貸借対照表と流動性
売上高
$137.20B
直近12か月（2026/3/31まで）
純利益
$1.13B
直近12か月（2026/3/31まで）
フリーキャッシュフロー
$375M
自己資本合計
$17.66B
負債合計
$31.17B
流動比率
1.77
利払い倍率
3.68
負債/EBITDA
4.11
一株当たり利益（EPS）
売上高と純利益
フリーキャッシュフロー
収益内訳
財務推移表
利益率の推移
負債の推移
負債の重さ
成長率グリッド
成長率 — 売上高
適正価値の推定
適正価値
$400.66
現在株価
$376.91
安全マージン
+5.9%
適正価値レンジ
$260.43 - $540.89
使用した評価手法間のばらつきであり、統計的に較正された信頼区間ではありません。
推定方法
バリュエーション指標
P/E レシオ
40.72
ROE
6.7%
P/B レシオ
2.47
P/FCF
36.02
粗利益率
-
ROIC
5.7%
収益性レーダー
価値創造（経済的モート）
ROIC
5.7%
WACC
7.2%
ROIC − WACC
-1.5 pp
ROICが資本コストを下回っています。投資した1ドルごとに企業は価値を破壊しています。
ファンダメンタル分析基準
合格（15）
- EPS shows upward trend
- Price CAGR 7.22%
- ROIC 5.7%
- P/B Ratio 2.47
- Debt/Equity ratio
- Positive Free Cash Flow
- Current Ratio
- Interest Coverage
- Debt/EBITDA
- Return on Tangible Assets
- Revenue Growth 5Y 10.9%
- Earnings Surprise avg 5.1%
- Earnings Quality (OCF/NI) 1.63
- Share Dilution -0.2%
- Piotroski F-Score 6/9
不合格（10）
- EPS CAGR 3.94%
- P/FCF 36.02
- Operating Margin 1.8%
- CapEx intensity
- Low reliance on intangibles
- Price below Graham Number
- DCF valuation (Overvalued)
- ROE 6.9%
- Analyst Consensus 48% Buy
- Net Margin Trend 0.8% vs 1.4%
データなし（3）
- Gross Margin NaN%
- Dividend Payout NaN%
- PEG Ratio (need PE > 0 and growth > 0)
Piotroski F-スコア
まちまちのシグナル：一部の領域に注意が必要
利益の質
高品質：利益はキャッシュに裏付けられている
株式希薄化
株式を買い戻している。株主に友好的
機関投資家の保有
ガバナンス
経営陣
| 氏名 | 役職 | 年齢 |
|---|---|---|
| Mr. James A. Rechtin M.B.A. | President, CEO & Director | 54 |
| Ms. Celeste Marie Mellet | Chief Financial Officer | 48 |
| Mr. Japan A. Mehta | Chief Information Officer | 44 |
| Ms. Michelle A. O'Hara | Chief Human Resources Officer | 49 |
| Dr. Sanjay K. Shetty M.B.A., M.D. | President of CenterWell | 51 |
| Mr. John-Paul William Felter | Senior VP, Chief Accounting Officer & Controller | 42 |
| Mr. Bobby Mukundan | Senior VP & CTO | - |
| Ms. Lisa M. Stoner | Vice President of Investor Relations | - |
| Mr. Joseph C. Ventura | Chief Legal Officer | 48 |
| Mr. Bruce Dale Broussard | Strategic Advisor | 63 |
監査リスク
2
取締役会リスク
2
報酬リスク
5
株主権利リスク
2
パート2 · 株価と買い時
この部分は企業に価値があるかを判断するものではありません。ファンダメンタルズに納得したうえで、いつ買うかを選ぶためのものです。内容：テクニカル分析、ポテンシャル、過去のドローダウン、ガンマエクスポージャー。
業績推移
via SEC EDGAR
Latest News
Recent headlines for HUM, sourced from Markets Gazette.
- 7/29/2026NEGATIVEHumana Lower on Profit Guidance; P&G Moves on Results | Stock Movers
Humana Inc. is experiencing a significant downturn as the health insurance provider maintained its annual profit guidance despite a robust second quarter performance. While the company delivered strong operational results for the period, the decision to keep the full-year outlook unchanged suggests potential headwinds or conservatism that has unnerved investors. This lack of upward revision, even with a positive quarterly showing, signals a cautious stance that could impact future revenue streams and profitability, leading to a sell-off in its shares.
via Markets Gazette